

# TREATMENT OF TUBERCULOSIS

## Guidelines for treatment of drug-susceptible tuberculosis and patient care

2017 UPDATE



World Health  
Organization



# TREATMENT OF TUBERCULOSIS

## Guidelines for treatment of drug-susceptible tuberculosis and patient care

**2017 UPDATE**



World Health  
Organization

Guidelines for treatment of drug-susceptible tuberculosis and patient care, 2017 update

ISBN 978-92-4-155000-0

© World Health Organization 2017

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”.

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

**Suggested citation.** Guidelines for treatment of drug-susceptible tuberculosis and patient care, 2017 update. Geneva: World Health Organization; 2017. Licence: CC BY-NC-SA 3.0 IGO.

**Cataloguing-in-Publication (CIP) data.** CIP data are available at <http://apps.who.int/iris>.

**Sales, rights and licensing.** To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

**Third-party materials.** If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

**General disclaimers.** The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Designed by Genève Design.

Printed in Switzerland.

WHO/HTM/TB/2017.05

---



# Contents

<b>Abbreviations &amp; acronyms</b>	<b>v</b>
<b>Acknowledgements</b>	<b>vi</b>
<b>Declaration and management of conflict of interest</b>	<b>viii</b>
<b>Executive summary</b>	<b>x</b>
Summary of changes in the new guidelines 2017 and policy recommendations on treatment of drug-susceptible TB and patient care in other existing WHO guidelines that remain valid	xv
<b>Introduction</b>	<b>1</b>
<b>Objectives</b>	<b>1</b>
<b>Methods used to update the guidelines</b>	<b>2</b>
Scope of the guideline update	2
Key questions	3
Certainty of evidence and strength of recommendations	3
Assessment of evidence and its grading	4
External review	6
Publication, dissemination, implementation, evaluation and expiry	7
<b>WHO policy recommendations</b>	<b>8</b>
<b>1. Treatment of drug-susceptible tuberculosis</b>	<b>8</b>
1.1. The effectiveness of 4-month fluoroquinolone-containing regimens when compared to the standard 6-month treatment regimen of 2HRZE/4HR in patients with drug-susceptible pulmonary TB disease	8
1.2. The effectiveness of TB treatment using fixed-dose combination tablets when compared to separate drug formulations in patients with drug-susceptible TB disease	10
1.3. The effectiveness of intermittent dosing (thrice weekly) of TB medications, both in the intensive phase and in the continuation phase of treatment, when compared to daily treatment	11
1.4. Initiation of antiretroviral treatment (ART) in TB patients living with HIV	13
1.5. The effectiveness of a TB treatment period of greater than 8 months compared to the standard 6-month treatment period for HIV co-infected patients with drug-susceptible pulmonary TB	15
1.6. The use of adjuvant steroids in the treatment of extrapulmonary TB disease	16
1.7. The empirical use of the WHO category II regimen in patients who require retreatment for TB	18



2. Patient care and support	20
2.1. Cross-cutting interventions for drug-susceptible TB and drug-resistant TB: effectiveness of patient care and support interventions	20
2.2. Model of care for drug-resistant TB: the benefits of treating MDR-TB patients within a decentralized compared to centralized model of care	29
<b>Research priorities</b>	<b>32</b>
<b>References</b>	<b>34</b>
<b>Annexes</b>	<b>46</b>
Annex 1: Experts involved in the development of the guidelines	47
Annex 2. PICO questions	50

**Annex 3. GRADE evidence profiles**  
**Annex 4. Evidence-to-decision tables**  
**Annex 5. Reports of the systematic reviews**

Are available on the Internet at:  
[http://www.who.int/tb/publications/  
2017/dstb\\_guidance\\_2017/en/](http://www.who.int/tb/publications/2017/dstb_guidance_2017/en/)



# Abbreviations & acronyms

AIDS	acquired immunodeficiency syndrome
ART	antiretroviral treatment
ATS	American Thoracic Society
BMI	body mass index
CDC	United States Centers for Disease Control and Prevention
DOT	directly observed treatment
E	Ethambutol
FDC	fixed-dose combination
GDG	Guideline Development Group
Gfx	Gatifloxacin
GRADE	Grading of Recommendations Assessment, Development and Evaluation
GTB	Global TB Programme
HIV	human immunodeficiency virus
IDSA	Infectious Diseases Society of America
IRIS	Immune Reconstitution Inflammatory Syndrome
KNCV	Royal Dutch Tuberculosis Foundation
MDR-TB	multidrug-resistant tuberculosis
Mfx	Moxifloxacin
NGO	non-governmental organization
PICO	Patients, Intervention, Comparator and Outcomes
RIF or R	Rifampicin
RFP	Rifapentine
SAT	self-administered treatment or unsupervised treatment
SMS	Short Message Service or text message
TB	tuberculosis
The Union	International Union Against Tuberculosis and Lung Disease
USAID	United States Agency for International Development
VOT	video-observed treatment
WHO	World Health Organization
XDR-TB	extensively drug-resistant tuberculosis



# Acknowledgements

The recommendations and remarks contained in this document were formulated by a Guideline Development Group (GDG) convened by the WHO Global TB Programme (GTB) of the World Health Organization (WHO) in Geneva, Switzerland, on 11-13 July 2016. WHO gratefully acknowledges the contributions of the members of the GDG.

Holger Schünemann (GRADE Methodologist) chaired the GDG meeting that compiled, synthesized and evaluated the evidence presented during the meeting which made the revision of this 2017 guidance document possible.

Experts on the GDG who provided advice prior to, during and after the meeting – Si Thu Aung; Frank Bonsu, Jeremiah Chakaya, Lucy Chesire, Daniela Cirillo, Poonam Dhavan, Kelly Dooley, Kathy Fiekert, Mike Frick, Andrei Mariandyshev, Nguyen Viet Nhung, Ejaz Qadeer, Abdul Hamid Salim, Simon Schaaf, Pedro Suarez, Carrie Tudor, Justin Wong Yun Yaw – are also acknowledged.

It is important to note that this work could not have been finalized without the contribution of the American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America (ATS/CDC/IDSA) with an agreement on sharing at an early stage the evidence profiles and results of systematic reviews on drug-susceptible TB treatment that were commissioned for the update of ATS/CDC/IDSA TB treatment guidelines.<sup>1</sup> This partnership also allowed the WHO Steering Committee to establish excellent collaboration with the same research teams on preparing and presenting evidence profiles for the GDG meeting. WHO wishes to express its gratitude to the following institutions: University of California, San Francisco, USA; McGill University in Montreal, Canada; The University of Sydney, Australia; Johns Hopkins Bloomberg School of Public Health, Baltimore, USA; and the University of British Columbia, Vancouver, Canada; and to the colleagues from them (Narges Alipanah, Leila Chaisson, Gregory Fox, Jennifer Ho, James Johnston, Richard Menzies, Cecily Miller, Payam Nahid).

The external reviewers who provided a review of the completed document – Bitte Dlodlo

预览已结束，完整报告链接和二维码如下：

[https://www.yunbaogao.cn/report/index/report?reportId=5\\_26476](https://www.yunbaogao.cn/report/index/report?reportId=5_26476)

